SCHEMBL6788769

SCHEMBL6788769

CCc1ccc(C2CCN(CCCCN)CC2)c(OCC2CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.42
SLC6A4 P31645 1/20 0.42
DRD2 P14416 1/20 0.39
HTR4 Q13639 6/20 0.38
PDE4B Q07343 1/20 0.38
SCN7A Q01118 1/20 0.37
SCN5A Q14524 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM5 P08912 1/20 0.37
ADRA2C P18825 1/20 0.37
CHRM3 P20309 1/20 0.37
HTR1D P28221 1/20 0.37
ADRA1B P35368 1/20 0.37
HTR2B P41595 1/20 0.37
HTR3A P46098 1/20 0.37
SIGMAR1 Q99720 2/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5937185 0.90 HRH3 (0.44) HRH3SLC6A4DRD2SIGMAR1KDM4E
SCHEMBL6710744 0.86 DRD2 (0.51) HRH3SLC6A4DRD2HTR4CHRM4
SCHEMBL6788764 0.86 HTR4 (0.42) HRH3DRD2HTR4PDE4BSCN7A
SCHEMBL6787753 0.83 DRD2 (0.47) DRD2ADRA1B
SCHEMBL6788133 0.81 SLC6A4 (0.46) HRH3SLC6A4DRD2SIGMAR1
SCHEMBL6783746 0.80 SLC6A4 (0.40) HRH3SLC6A4DRD2ADRA1BSIGMAR1
SCHEMBL6811485 0.79 SLC6A4 (0.39) HRH3SLC6A4DRD2HTR4CHRM4
SCHEMBL5899886 0.78 HRH3 (0.40) HRH3SLC6A4KDM4E
SCHEMBL3107904 0.78 SLC6A4 (0.44) SLC6A4DRD2KDM4E
Hydrochloric Acid SCHEMBL6710614 0.77 SLC6A4 (0.43) SLC6A4DRD2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147557-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression BOUILLOT ANNE (FR) 2004-07-29 US claimed
EP-1351937-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP claimed
WO-2002055497-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO claimed
US-20040147557-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression BOUILLOT ANNE (FR) 2004-07-29 US disclosed
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression SMITHKLINE BEECHAM CORPORATION 2004-04-15 US disclosed
EP-1351935-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP disclosed
EP-1351937-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP disclosed
WO-2002055495-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO disclosed
WO-2002055497-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147557-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression NR1H2, NR1H3, NR1H4 HRH3 423/4885SLC6A4 969/4885DRD2 152/4885
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression NR1H2, NR1H3, NR1H4 HRH3 561/4885SLC6A4 812/4885DRD2 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.